270 related articles for article (PubMed ID: 32645298)
21. Inducible localized delivery of an anti-PD-1 scFv enhances anti-tumor activity of ROR1 CAR-T cells in TNBC.
Harrasser M; Gohil SH; Lau H; Della Peruta M; Muczynski V; Patel D; Miranda E; Grigoriadis K; Grigoriadis A; Granger D; Evans R; Nathwani AC
Breast Cancer Res; 2022 Jun; 24(1):39. PubMed ID: 35659040
[TBL] [Abstract][Full Text] [Related]
22. Longitudinal PET imaging demonstrates biphasic CAR T cell responses in survivors.
Vedvyas Y; Shevlin E; Zaman M; Min IM; Amor-Coarasa A; Park S; Park S; Kwon KW; Smith T; Luo Y; Kim D; Kim Y; Law B; Ting R; Babich J; Jin MM
JCI Insight; 2016 Nov; 1(19):e90064. PubMed ID: 27882353
[TBL] [Abstract][Full Text] [Related]
23. ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models.
Wallstabe L; Göttlich C; Nelke LC; Kühnemundt J; Schwarz T; Nerreter T; Einsele H; Walles H; Dandekar G; Nietzer SL; Hudecek M
JCI Insight; 2019 Sep; 4(18):. PubMed ID: 31415244
[TBL] [Abstract][Full Text] [Related]
24. Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade.
Srivastava S; Furlan SN; Jaeger-Ruckstuhl CA; Sarvothama M; Berger C; Smythe KS; Garrison SM; Specht JM; Lee SM; Amezquita RA; Voillet V; Muhunthan V; Yechan-Gunja S; Pillai SPS; Rader C; Houghton AM; Pierce RH; Gottardo R; Maloney DG; Riddell SR
Cancer Cell; 2021 Feb; 39(2):193-208.e10. PubMed ID: 33357452
[TBL] [Abstract][Full Text] [Related]
25. Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered Lymphocytes.
Krebs S; Ahad A; Carter LM; Eyquem J; Brand C; Bell M; Ponomarev V; Reiner T; Meares CF; Gottschalk S; Sadelain M; Larson SM; Weber WA
J Nucl Med; 2018 Dec; 59(12):1894-1900. PubMed ID: 29903928
[TBL] [Abstract][Full Text] [Related]
26. PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells.
Bajor M; Graczyk-Jarzynka A; Marhelava K; Burdzinska A; Muchowicz A; Goral A; Zhylko A; Soroczynska K; Retecki K; Krawczyk M; Klopotowska M; Pilch Z; Paczek L; Malmberg KJ; Wälchli S; Winiarska M; Zagozdzon R
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35078921
[TBL] [Abstract][Full Text] [Related]
27. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells.
Han Y; Xie W; Song DG; Powell DJ
J Hematol Oncol; 2018 Jul; 11(1):92. PubMed ID: 29980239
[TBL] [Abstract][Full Text] [Related]
28. Direct and Indirect Chimeric Antigen Receptor T-Cell Imaging with PET/MRI in a Tumor Xenograft Model.
Kim SY; Soh H; Jung JH; Cho EH; Kim H; Ju JM; Sheen JH; Lee SJ; Oh SJ; Lee SJ; Chung J; Ryu JS
Radiology; 2024 Feb; 310(2):e231406. PubMed ID: 38411517
[TBL] [Abstract][Full Text] [Related]
29. Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib.
Qin JS; Johnstone TG; Baturevych A; Hause RJ; Ragan SP; Clouser CR; Jones JC; Ponce R; Krejsa CM; Salmon RA; Ports MO
J Immunother; 2020 May; 43(4):107-120. PubMed ID: 31899702
[TBL] [Abstract][Full Text] [Related]
30. Engineered IL-7 Receptor Enhances the Therapeutic Effect of AXL-CAR-T Cells on Triple-Negative Breast Cancer.
Zhao Z; Li Y; Liu W; Li X
Biomed Res Int; 2020; 2020():4795171. PubMed ID: 31998790
[TBL] [Abstract][Full Text] [Related]
31. CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models.
Li H; Ding J; Lu M; Liu H; Miao Y; Li L; Wang G; Zheng J; Pei D; Zhang Q
J Immunother; 2020 Jan; 43(1):16-28. PubMed ID: 31574023
[TBL] [Abstract][Full Text] [Related]
32. Emerging Immunotherapies against Novel Molecular Targets in Breast Cancer.
Sivaganesh V; Promi N; Maher S; Peethambaran B
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33670942
[TBL] [Abstract][Full Text] [Related]
33. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
34. EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC.
Liu Y; Zhou Y; Huang KH; Li Y; Fang X; An L; Wang F; Chen Q; Zhang Y; Shi A; Yu S; Zhang J
Aging (Albany NY); 2019 Dec; 11(23):11054-11072. PubMed ID: 31804974
[TBL] [Abstract][Full Text] [Related]
35. Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy.
Ghassemi S; Milone MC
J Vis Exp; 2019 Dec; (154):. PubMed ID: 31904011
[TBL] [Abstract][Full Text] [Related]
36. TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer.
Byrd TT; Fousek K; Pignata A; Szot C; Samaha H; Seaman S; Dobrolecki L; Salsman VS; Oo HZ; Bielamowicz K; Landi D; Rainusso N; Hicks J; Powell S; Baker ML; Wels WS; Koch J; Sorensen PH; Deneen B; Ellis MJ; Lewis MT; Hegde M; Fletcher BS; St Croix B; Ahmed N
Cancer Res; 2018 Jan; 78(2):489-500. PubMed ID: 29183891
[TBL] [Abstract][Full Text] [Related]
37. Adenovirus-mediated specific tumor tagging facilitates CAR-T therapy against antigen-mismatched solid tumors.
Tang X; Li Y; Ma J; Wang X; Zhao W; Hossain MA; Yang Y
Cancer Lett; 2020 Sep; 487():1-9. PubMed ID: 32454143
[TBL] [Abstract][Full Text] [Related]
38. CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice.
Porcellini S; Asperti C; Corna S; Cicoria E; Valtolina V; Stornaiuolo A; Valentinis B; Bordignon C; Traversari C
Front Immunol; 2020; 11():99. PubMed ID: 32117253
[TBL] [Abstract][Full Text] [Related]
39. Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.
Porter CE; Rosewell Shaw A; Jung Y; Yip T; Castro PD; Sandulache VC; Sikora A; Gottschalk S; Ittman MM; Brenner MK; Suzuki M
Mol Ther; 2020 May; 28(5):1251-1262. PubMed ID: 32145203
[TBL] [Abstract][Full Text] [Related]
40. Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy.
Mo F; Duan S; Jiang X; Yang X; Hou X; Shi W; Carlos CJJ; Liu A; Yin S; Wang W; Yao H; Yu Z; Tang Z; Xie S; Ding Z; Zhao X; Hammock BD; Lu X
Signal Transduct Target Ther; 2021 Feb; 6(1):80. PubMed ID: 33627635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
